The future of healthcare is moving toward personalised medicine, as scientific insights allow patients to receive treatments selected to match their medical profile. The new Future Manufacturing Hub in Targeted Healthcare will allow UK manufacturers to develop and provide these biological medicines at an affordable cost.
Led by Professor Nigel Titchener-Hooker, Dean of UCL Engineering and Professor of Biochemical Engineering, it is one of 6 Engineering and Physical Sciences Research Council (EPSRC) research hubs announced in December that will explore and improve new manufacturing techniques in fields such as medical devices and 3D printing. UCL is also a partner in the Future Compound Semiconductor Manufacturing Hub.
The hubs will draw together expertise from 17 universities and multiple industrial and academic partners – the Targeted Healthcare incorporates a broad range representative of the UK sector including suppliers, manufacturers and regulators
Announcing this major investment in the UK’s manufacturing research base, Universities and Science Minister Jo Johnson said:
“Developing new innovative manufacturing techniques will help UK industry create new products, explore more business opportunities and ensure the UK becomes more competitive and productive.
This investment will lay the foundations to allow industry and our world-leading universities to thrive for years to come and is exactly the type of project that our upcoming Industrial Strategy will look to support.”
Professor Philip Nelson, EPSRC’s Chief Executive, said:
“Some of these new Hubs will build on the solid foundations of earlier Centres for Innovative Manufacturing while some, like the Hubs at the University of Sheffield, are completely new ventures that have strong links with industry and organisations such as the Advanced Manufacturing Research Centre. EPSRC is pleased to be at the forefront of the drive to keep the UK a prosperous and productive nation.”
The Future Manufacturing Hub in Targeted Healthcare will bring forward the ability to treat patients as individuals, developing not only technologies, but also the associated intellectual property and skilled personnel needed. Hub leader, Professor Nigel Titchener Hooker, said:
“This hub will fill a major gap in the development of personalised healthcare – reinventing a drug discovery process so that these treatments make it to market at affordable prices. We’re enthused about growing this skilled manufacturing industry.”
The academic partners for the Targeted Healthcare hub are UCL, University of Warwick, Imperial College London, The University of Manchester, University of Nottingham, Loughborough University.
Industrial partners are: Albumedix, Allergan, AstraZeneca/Medimmune, Autolus, BIA Separation, BioIndustry Association, BiologicB Consulting, BioPharm Services, Cell & Gene Therapy Catapult , CPI/NBMC, DeltaDot, Eli Lilly, FloDesignSonics, Francis BioPharm Consulting , Fujifilm Diosynth Biotechnologies, GlaxoSmithKline (Biopharma) & GlaxoSmithKline (Cell/Gene Therapy), KTN Ltd, LGC, Lonza, Merck & Co., Merck KGaA, MMIP, NIBSC, Novo Nordisk, Oxford BioMedica, Perceptive, Pfizer, Puridify, Purolite Ltd, Reneuron, Roche, Sartorius, Sutro Biopharma, Tillingbourne Consulting, TrakCel, UCB Pharma, Wyatt